ALECTINIB for Non-small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 1,946 adverse event reports in the FDA FAERS database where ALECTINIB was used for Non-small cell lung cancer.
Most Reported Side Effects for ALECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 702 | 7.7% | 697 | 23 |
| Fatigue | 618 | 6.8% | 12 | 78 |
| Constipation | 525 | 5.7% | 16 | 77 |
| Off label use | 495 | 5.4% | 43 | 43 |
| No adverse event | 488 | 5.3% | 0 | 2 |
| Disease progression | 366 | 4.0% | 64 | 31 |
| Rash | 312 | 3.4% | 5 | 54 |
| Dyspnoea | 296 | 3.2% | 22 | 110 |
| Drug ineffective | 269 | 2.9% | 47 | 25 |
| Myalgia | 268 | 2.9% | 1 | 21 |
| Anaemia | 267 | 2.9% | 9 | 47 |
| Asthenia | 258 | 2.8% | 15 | 38 |
| Weight increased | 237 | 2.6% | 2 | 18 |
| Nausea | 225 | 2.5% | 10 | 59 |
| Diarrhoea | 204 | 2.2% | 13 | 40 |
Other Indications for ALECTINIB
Lung neoplasm malignant (2,932)
Product used for unknown indication (1,303)
Non-small cell lung cancer metastatic (627)
Lung adenocarcinoma (575)
Lung cancer metastatic (421)
Bronchial carcinoma (339)
Neoplasm malignant (211)
Metastases to central nervous system (120)
Lung carcinoma cell type unspecified stage 0 (71)
Metastases to bone (71)
Other Drugs Used for Non-small cell lung cancer
NIVOLUMAB (9,987)
CARBOPLATIN (7,939)
PEMBROLIZUMAB (6,893)
OSIMERTINIB (6,358)
PEMETREXED (5,179)
PACLITAXEL (4,609)
ATEZOLIZUMAB (4,459)
BEVACIZUMAB (4,136)
DURVALUMAB (3,396)
ERLOTINIB (3,359)